Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
HOME > ARCHIVE
ARCHIVE
- EPS Goes Public, First Listed CRO in Japan
June 4, 2001
- COPRORATE ROUNDUP NEWS IN BRIEF -4-
June 4, 2001
- BUSINESS NEWS IN BRIEF
June 4, 2001
- COPRORATE ROUNDUP NEWS IN BRIEF -5-
June 4, 2001
- JACDS Makes Proposals for Nursing Care Business at Drugstores
June 4, 2001
- Wholesalers' Profits Plummet due to Tough Negotiation on Price
June 4, 2001
- Fujisawa Licenses Osteoporosis Drug from Servier
June 4, 2001
- COPRORATE ROUNDUP NEWS IN BRIEF -1-
June 4, 2001
- Shionogi to Launch MS Contin in Small Packages
June 4, 2001
- COPRORATE ROUNDUP NEWS IN BRIEF -2-
June 4, 2001
- Takeda to Increase OTC Sales to \100 Bil. in 2005
June 4, 2001
- COPRORATE ROUNDUP NEWS IN BRIEF -3-
June 4, 2001
- Efco, Kyuyukai to Merge in Fall
June 4, 2001
- Continuing Growth by Focusing on Specialty Pharmaceuticals: Mr Pyott of Allergan
June 4, 2001
- Takiya Shoji, Drux to Merge in August
June 4, 2001
- Listing of 14 Active Ingredients Including Radicut, Zyprexa Approved
June 4, 2001
- Taisho Terminates Business with Daikoku Group
June 4, 2001
- Peak-time Sales of Radicut, Zyprexa Expected to Top \10 Bil.
June 4, 2001
- NEW PRODUCTS NEWS IN BRIEF
June 4, 2001
- Chuikyo to Review NHI Pricing Rule
June 4, 2001
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…